Li Na Ma
Direktor/Vorstandsmitglied bei SICHUAN HUIYU PHARMACEUTICAL CO., LTD.
Profil
Li Na Ma is currently the Chief Executive Officer at Staidson Hong Kong Investment Co. Ltd., the Chairman at Beijing Defengrei Biotechnology Co. Ltd., the Secretary, Director & Deputy General Manager at Sichuan Huiyu Pharmaceutical Co., Ltd., the General Manager at Zhejiang Staidson Investment Co., Ltd., and the Secretary at Staidson Biopharma, Inc. Ms. Ma previously worked as a Director at InflaRx GmbH, the Secretary, Director & Deputy General Manager at Staidson (Beijing) Biopharmaceuticals Co., Ltd., a Non-Executive Director at InflaRx NV, and the General Manager at JOINN Laboratories (China) Co., Ltd.
Ms. Ma holds an MBA from HKU School of Professional & Continuing Education and an undergraduate degree from Hunan University of Chinese Medicine.
Aktive Positionen von Li Na Ma
| Unternehmen | Position | Beginn |
|---|---|---|
| SICHUAN HUIYU PHARMACEUTICAL CO., LTD. | Direktor/Vorstandsmitglied | 26.04.2023 |
| Beijing Defengrei Biotechnology Co. Ltd. | Vorsitzender | 01.09.2015 |
Staidson Biopharma, Inc.
 Staidson Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Staidson Biopharma, Inc. is an American company that focuses on researching and developing biotechnology. | Unternehmenssekretär | 01.01.2013 |
Staidson Hong Kong Investment Co. Ltd.
 Staidson Hong Kong Investment Co. Ltd. Investment ManagersFinance Part of Staidson (Beijing) Biopharmaceuticals Co., Ltd., Staidson Hong Kong Investment Co. Ltd. provides asset management services. The company is based in Hong Kong, Hong Kong. Li Na Ma has been the CEO of the Chinese company since 2015. | Vorstandsvorsitzender | 01.01.2015 |
Zhejiang Staidson Investment Co., Ltd.
 Zhejiang Staidson Investment Co., Ltd. Investment ManagersFinance Zhejiang Staidson Investment Co., Ltd. engages in investment industry. It services include Industrial Investment, Investment Management, Investment Consulting, and Business Management Consulting. The company was founded on June 27, 2017 and is headquartered in Zhejiang, China. | Vorstandsvorsitzender | 01.06.2017 |
Ehemalige bekannte Positionen von Li Na Ma
| Unternehmen | Position | Ende |
|---|---|---|
| STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. | Direktor/Vorstandsmitglied | 31.12.2021 |
| JOINN LABORATORIES(CHINA)CO.,LTD. | Corporate Officer/Principal | 01.01.2009 |
| INFLARX N.V. | Direktor/Vorstandsmitglied | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Direktor/Vorstandsmitglied | - |
Ausbildung von Li Na Ma
| HKU School of Professional & Continuing Education | Masters Business Admin |
| Hunan University of Chinese Medicine | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. | Health Technology |
| JOINN LABORATORIES(CHINA)CO.,LTD. | Health Technology |
| INFLARX N.V. | Health Technology |
| SICHUAN HUIYU PHARMACEUTICAL CO., LTD. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
Zhejiang Staidson Investment Co., Ltd.
Zhejiang Staidson Investment Co., Ltd. Investment ManagersFinance Zhejiang Staidson Investment Co., Ltd. engages in investment industry. It services include Industrial Investment, Investment Management, Investment Consulting, and Business Management Consulting. The company was founded on June 27, 2017 and is headquartered in Zhejiang, China. | Finance |
| Beijing Defengrei Biotechnology Co. Ltd. | |
Staidson Biopharma, Inc.
Staidson Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Staidson Biopharma, Inc. is an American company that focuses on researching and developing biotechnology. | Commercial Services |
Staidson Hong Kong Investment Co. Ltd.
Staidson Hong Kong Investment Co. Ltd. Investment ManagersFinance Part of Staidson (Beijing) Biopharmaceuticals Co., Ltd., Staidson Hong Kong Investment Co. Ltd. provides asset management services. The company is based in Hong Kong, Hong Kong. Li Na Ma has been the CEO of the Chinese company since 2015. | Finance |
